secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2023-02-13T23:59:59+00:00
Accession:  0001493152-23-004490
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 1.02, 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte amends Chronix earnout; ends Thermo Fisher partnership; gets Nasdaq extension
--------------------------------------------------------------------------------

- Amended Merger Agreement: milestone payments and 15% royalty replaced with 10% of net collections until IP expiry, plus 5% of gross proceeds from transplant patent sale.
- Terminated Collaboration Agreement with Life Technologies (Thermo Fisher) for IVD development; pays $680,695 termination payments; $1.125M service contract canceled.
- Common stock transferred from Nasdaq Global Market to Capital Market; granted additional 180-day period to regain $1.00 bid price compliance.
- Earnout consideration now solely cash; original milestone payments, 15% royalty, and transplant transfer payout eliminated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223004490/0001493152-23-004490-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223004490/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-004490

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer